Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test [Yahoo! Finance]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Yahoo! Finance
CHICAGO, November 07, 2024 BUSINESS WIRE )--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (ICI)-based therapy. Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which demonstrated that IPS-High patients in the study were more likely to have an overall survival benefit while receiving ICI-based therapy than IPS-Low patients in the study (HR 0.45). Tempus validated IPS in a retrospective study involving 1,600 metastatic and/or stage IV adult patients with 19 different solid tumor types fro
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.MarketBeat
- Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®Business Wire
- Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer CareBusiness Wire
- Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.MarketBeat
- Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
TEM
Earnings
- 11/4/24 - Miss
TEM
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/5/24 - Form 4
- TEM's page on the SEC website